An Extension Study of 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids

NCT02811159 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

20

Enrollment

INDUSTRY

Sponsor class

Stopped Business decision

Conditions

Uterine Fibroids

Interventions

DRUG: Telapristone acetate

Sponsor

Repros Therapeutics Inc.